Open Access

An overview of treatment response rates to various anti-viral drugs in Pakistani Hepatitis B Virus infected patients

  • Liaqat Ali1Email author,
  • Muhammad Idrees1Email author,
  • Muhammad Ali1,
  • Irshad-ur Rehman1,
  • Abrar Hussain1,
  • Samia Afzal1,
  • Sadia Butt1,
  • Sana Saleem1,
  • Saira Munir1 and
  • Sadaf Badar1
Virology Journal20118:20

https://doi.org/10.1186/1743-422X-8-20

Received: 5 December 2010

Accepted: 15 January 2011

Published: 15 January 2011

Abstract

Hepatitis B virus (HBV) is one of the leading health problem with up to 350 million affected people worldwide including 4.5 million only in Pakistan. It has mortality rate of 0.5 to 1.2 million per year worldwide. Pakistan lies in the endemic region with 3-5% HBV carrier rate in the country. The present article reviews the literature on the treatment response of HBV prevalent in Pakistani population. The average treatment response of Lamivudine and interferon-α is 25.81% and 47.95%, respectively. Peg-Interferon was shown to be not effective against the HBV/HCV (hepatitis C virus)/HDV (hepatitis Delta virus) co-infection. The present study reveals that interferon-α is the most effective therapy available for HBV infection prevalent in Pakistani population. Genotype C & D are the most common HBV genotypes in Pakistan and are associated with increased severity and less response to interferon therapy. This poses a great challenge for physicians and researchers and further studies are needed to describe the outcome of the current therapies recommended against HBV infection in Pakistani population.

Introduction

Hepatitis B virus (HBV) is a crucial health problem with up to 350 million affected people worldwide [1]. HBV is a member of the Hepadnaviridae family with 3.2 kilobase pair DNA genome which is partially double-stranded [2, 3]. Pre-s domain surface protein is mediates its attachment to the cell membrane [4].

Several previous studies on the association of the HBV genotypes with disease progression reported that genotypes B and C are correlated with severity of liver dysfunction while high viral loads were observed in patients infected with genotype C [5, 6], A, and D [7] in some studies but not in others [8, 9]. According to WHO, Pakistan has low HBV infection rates of 3%, while studies from Pakistan are more focused towards the HBV prevalence rate [10, 11], epidemiological issues [12], genotyping and its core antigen genetic variability [13].

Approved drugs advised for the treatment of HBV include interferon-α, PEG-interferon and antiviral drugs like lamivuaine, adefovir, dipivoxil, entecavir and telbivudine. Hepatitis B antibodies and the HBV vaccine within 12 hours of birth help to prevent the infection [14]. In Pakistan, there are estimated 4.5 million carriers of HBV with a carrier rate of 3-5%. However, studies are limited describing HBV treatment response in Pakistani population. The present article reviews all the available literature on the treatment response to the available therapies against HBV prevalent in Pakistani population (Table 1).
Table 1

An overview of treatment outcome in Pakistani HBV treated patients

Author

Region

Patients (n)

Etiology

Treatment

Duration (weeks)

Results

Qureshi et al:[19]

Karachi

69

HBeAg, HBV DNA positive patients

100 mg of Lamivudine orally before breakfast till seroconversion

36 months

38% cases were observed to sero-converted.

Qureshi et al: [19]

Karachi

55

HBV DNA positive (wild type) with delta positive

100 mg of Lamivudine orally before breakfast till seroconversion

36 months

16.4% cases in group 2 sero-converted (Wild type of HBV/HDV co-infected cases have a 16% chance of seroconversion)

Naeem et al:[31]

Rawalpindi

50

Chronic viral hepatitis B (HBsAg and HBV DNA positive)

5 mega units of recombinant interferon alfa-2b subcutaneously once daily

4-months

HBV DNA was found negative in 44.0% (22) patients while treatment was ceased in three patients due to severe depression.

Zuberi et al: [21]

Karachi

246

co/super-infection of Hepatitis C and D among patients of HBV

pegylated interferon-a 2a 180 mcg sc weekly

48 weeks

HBV was not cleared in any case

Zuberi et al: [32]

Karachi

52

patients of hepatitis B with hepatitis D

Interferon - a 10.0 MIU sc t.i.w.

48 weeks

51.9% patients had suppressed (< 400 copies/ml) HBV DNA levels

Khokhar et al. [21]

Islamabad

105

positive HBsAg and elevated ALT

lamivudine 100 mg once a day for 12 months

12 months and were followed every 2-3 months with ALT, HBeAg and HBV DNA

HBeAg positive and HBeAg negative patients were found with 23.6% and 80.0% treatment response rate respectively (All the patients were HBsAg positive)

Anti viral efficacy of lamivudine

A nucleoside analogue called lamivudine, has anti-HBV and anti-HIV properties, was approved by the US-FDA in 1998 for the treatment of HBV infections. It is administered orally with concentration of 100 mg/day [15]. Use of lamivudine is reported to decrease the circulating DNA levels of HBV [16, 17] while long term decrease has been achieved after one month's therapy [18]. In Pakistani population, the rate of seroconversion against lamivudine was observed to be 16% in HBV/HDV(Hepatitis delta Virus) co-infected patients when administered for 36 months [19], 23 to 38% in HBV infected patients when administered for 12 months and 36 months, respectively (Table 1) [20, 21]. A much higher HBV response rate is being observed in Pakistani population than reported earlier [22]. These studies show that lamivudine monotherapy is a better option for treatment of HBV infection but this therapy require longer durations (up to 36 months) and develop increased resistance (up to 20% after one year and 70% after 5 years of therapy) [23, 24], which makes it undesirable for the patients.

Nucleotide and nucleoside analogues are shown to be associated with minimum side effects as compared to the standard INF and PEG-INF therapies. These include short term adversed effects like myopathy, neuropathy and lactic acidosis [25]. These include side effects like abdominal pain, headache, cough, nasopharyngitis, pyrexia, diarrhea and fatigue [26].

Anti viral efficacy of Peg-Interferon

Interferon is supplemented with polyethylene glycol (PEG) which prolongs its half-life resulting in sustained antiviral response rates. Two types of PEG-IFN have been studied for HBV therapy, PEG-IFN α-2a having a large 40 kDa PEG branched and PEG-IFN α-2b with a 12 kDa PEG molecule [27]. Buster and Janssen [22] reported HBV treatment response of 19-35% by administration of peg-IFN. However, administration of pegylated interferon-α 2a for 4 months failed to treat the HBV, HDV and HCV co-infection in Pakistani population [20] and is associated with adverse effects like depression, flu-like symptoms, neuropsychiatric disorders and suppression of bone marrow [28].

This shows that peg-interferon is not effective against HBV when administered in HBV/HDV/HCV co-infected patients. However, there is no study describing the use of peg-interferon against HBV infected Pakistani population.

Anti viral efficacy of Interferon-α (IFN-α)

IFN-α was approved in 1992 after being extensively studied. It is reported to increase hepatitis B surface antigen (HBsAg) expression by hepatocytes and inhibit packaging of pre-genomic viral RNA into the core particles [29]. Currently, many different types of interferon are available but available data is limited to support advantage of one therapy to be more effective than the others. However, the response rate of 30-40% was reported by the administration of IFN-α for 6-12 months as compared to 10-20% in controls. Patients with lower ALT and/or higher HBV viral loads and immunosuppressed patients are the risk factors that result in decreased response to IFN treatment. Hepatitic flares are shown to predict sustained virological response during interferon treatment [30]. Naeem and coworkers [31] reported that administration of 5MIU of recombinant IFN-α-2b for four months lead to response in 44% of Pakistani patients. On the other hand, Zuberi and colleagues [32] described an increased treatment response of 51.9% after administration of 10.0 MIU of IFN-α in HBV infected patients for the same period of 16 weeks. IFN-α is also shown to be associated with the development of side effects like insomnia, fatigue, alopecia and anorexia [33, 34]. However, further studies on the treatment response and follow up of patients are needed to understand the effectiveness of INF-α against HBV infection in Pakistani population.

HBV genetic heterogeneity and Antiviral Therapy

HBV has been classified into 9 genotypes (A-I) based on 8% or more inter-group divergence in full length genomic sequence [3538] and its antiviral treatment response rate is highly affected by genetic variability as well as by various host and viral factors.

The most recent study conducted throughout Pakistan has reported that HBV genotype C is the most prevalent genotype in Pakistan with 26.7% prevalence, followed by genotype B (18%), A (14.3%), D (13%), mixed genotypes (14.6%) and 10.3% were found untypable [38]. While genotypes E (0.6%) and F (1.3%) have been reported recently in Pakistan. A very high prevalence of HBV genotype D (60-100%) were also reported from different regions of Pakistan [3944, 13]. It is well understood that both genotype C & D are less responsive to interferon therapy and associated with more severe disease than genotype A and B [45, 46]. Moreover, these genotypes are reported to be less frequently related to HBeAg clearance rates than genotypes A and B when treated with pegylated interferon [47]. Another study revealed that antiviral response rate against IFN-alpha was higher in genotype F as compared to genotypes E and G [48].

The high prevalence of HBV genotype D and C in Pakistani population and its association with increased severity of the disease and resistance to the present therapies demands more consistent preventive measures like mass vaccination and awareness programs at national level.

Conclusion

This review explains that interferon-α is the most effective available drug against the HBV prevalent in Pakistan with up to 47.95% treatment response rate. Moreover, treatment of the resistant but most prevalent HBV genotypes C and D is a challenge for clinicians and scientists in our region. However, further studies are needed to fully describe the treatment response and the risk factors of the currently recommended therapies against HBV infection especially combination therapy of interferon and lamivudine in Pakistani isolates. These future prospects will enable the virologists to focus drug designing in this part of the world.

Declarations

Authors’ Affiliations

(1)
Division of Molecular Virology, National Centre of Excellence in Molecular Biology, University of the Punjab

References

  1. Awan Z, Idrees M, Rafique S, Rehman I, Akbar H, But S, et al.: Hepatitis B virus YMDD-motif mutations with emergence of lamivudine-resistant mutants: a threat to recovery. Gastroenterology and Hepatology From Bed to Bench 2010, 3: 108-114.Google Scholar
  2. Lee W: Hepatitis B virus infection. N Engl J Med 1997, 337: 1733-1745. 10.1056/NEJM199712113372406View ArticlePubMedGoogle Scholar
  3. Ganem D, Schneiden RJ, et al.: Hepadnaviridae: the viruses and their replication. In Fields Virology. Edited by: Knipe DM, Howely PM, Griffin DE. Philadelphia: Lippincott-Raven; 2001:292-2969.Google Scholar
  4. Klingmuller U, Schallen H: Hepadnavirus infection requires interaction between the viral pre-s domain and a specific hepatocellular receptor. J Virol 1993, 67: 7414-7422.PubMed CentralPubMedGoogle Scholar
  5. Sugauchi F, Chutaputti A, Orito E, Kato H, Suzuki S, Ueda R, Mizokami M: Hepatitis B virus genotypes and clinical manifestation among hepatitis B carriers in Thailand. J Gastroenterol Hepatol 2002, 17: 671-676. 10.1046/j.1440-1746.2002.02754.xView ArticlePubMedGoogle Scholar
  6. Ishikawa K, Koyama T, Masuda T: Prevalence of HBV genotypes in asymptomatic carrier residents and their clinical characteristics during long-term follow-up: the relevance to changes in the HBeAg/anti-HBe system. Hepatol Res 2002, 24: 1. 10.1016/S1386-6346(02)00017-7View ArticlePubMedGoogle Scholar
  7. Westland C, Delaney W, Yang H, Gibbs C, Miller M, Wulfsohn MJ: Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology 2003, 125: 107-116. 10.1016/S0016-5085(03)00700-5View ArticlePubMedGoogle Scholar
  8. Sumi H, Yokosuka O, Seki N, Arai M, Imazeki F, Kurihara T, Kanda T, Fukai K, Kato M, Saisho H: Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology 2003, 37: 19-26. 10.1053/jhep.2003.50036View ArticlePubMedGoogle Scholar
  9. Orito E, Mizokami M, Sakugawa H, Michitaka K, Ishikawa K, Ichida T, et al.: A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. Hepatology 2001, 33: 218-223. 10.1053/jhep.2001.20532View ArticlePubMedGoogle Scholar
  10. Khichi GQK, Channar MS: Prevalence of hepatitis B carriers among children in Bahawalpur urban slums. Pak J Med Sci 2000, 16: 238-241.Google Scholar
  11. Khattak MF, Salamat N, Bhatti FA, Qureshi TZ: Seroprevalence of hepatitis B, C and HIV in blood donors in northern Pakistan. J Pak Med Assoc 2002, 52: 398-402.PubMedGoogle Scholar
  12. Akhtar S, Younus M, Adil S, Hassan F, Jafri SH: Epidemiologic study of chronic hepatitis B virus infection in male volunteer blood donors in Karachi, Pakistan. BMC Gastroenterol 2005, 5: 26. 10.1186/1471-230X-5-26PubMed CentralView ArticlePubMedGoogle Scholar
  13. Abbas Z, Muzaffar R, Siddiqui A, Naqvi SAA, Rizvi SAH: Genetic variability in the precore and core promoter regions of hepatitis B virus strains in Karachi. BMC Gastroenterol 2006, 6: 20. 10.1186/1471-230X-6-20PubMed CentralView ArticlePubMedGoogle Scholar
  14. Gilroy RK, Mukherjee S: Hepatitis A. Kanas Med Centre 2008.Google Scholar
  15. Cammack N, Rouse P, Marr CL, Reid PJ, Boehme RE, Coates JA, Penn CR, Cameron JM: Cellular metabolism of (-) enantiomeric 2'-deoxy-3'-thiacytidine. Biochem Pharmacol 1992, 43: 2059-2064. 10.1016/0006-2952(92)90162-CView ArticlePubMedGoogle Scholar
  16. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al.: Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999, 341: 1256-1263. 10.1056/NEJM199910213411702View ArticlePubMedGoogle Scholar
  17. Lai CL, Chine RW, Leung NWY, Chang TT, Guan R, Tai DI, et al.: A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998, 339: 61-68. 10.1056/NEJM199807093390201View ArticlePubMedGoogle Scholar
  18. Yuen MF, Fong DY, Wong DK, Yuen JC, Fung J, Lai CL: Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology 2007, 46: 1695-1703. 10.1002/hep.21939View ArticlePubMedGoogle Scholar
  19. Qureshi H, Arif A, Alam E: Treatment of HBV and HDV co-infection using lamivudine. J Ayub Med Coll Abbottabad 2009, 21: 1-3.PubMedGoogle Scholar
  20. Zuberi BF, Afsar S, Quraishy MS: Triple Hepatitis: Frequency and Treatment Outcome of co/super-Infection of Hepatitis C and D Among Patients of Hepatitis B. J Coll Physicians Surg Pak 2008, 18: 404-407.PubMedGoogle Scholar
  21. Khokhar N, Gill ML, Alam AY: Treatment of chronic Hepatitis B with Lamivudine. J Coll Physicians Surg Pak 2005, 15: 78-80.PubMedGoogle Scholar
  22. Buster EHCJ, Janssen HLA: Antiviral treatment for chronic hepatitis B virus infection-immune modulation or viral suppression? The Journal of Medicine 2006, 64: 175-185.Google Scholar
  23. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, et al.: Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003, 125: 1714-1722. 10.1053/j.gastro.2003.09.033View ArticlePubMedGoogle Scholar
  24. Pawlotsky JM, Dusheiko G, Hatzakis A, Lau D, Lau G, Liang TJ, et al.: Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 2008, 134: 405-415. 10.1053/j.gastro.2007.11.036PubMed CentralView ArticlePubMedGoogle Scholar
  25. Sonneveld MJ, Janssen HLA: Pros and cons of peginterferon versus nucleos(t)ide analogues for treatment of chronic hepatitis B. Curr Hepatitis Rep 2010, 9: 91-98. 10.1007/s11901-010-0041-7View ArticleGoogle Scholar
  26. Chang T, Gish RG, de-Man R, Gadano A, Sollano J, Chao Y, et al.: A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B. N Engl J Med 2006, 354: 1001-10. 10.1056/NEJMoa051285View ArticlePubMedGoogle Scholar
  27. Craxi A, Cooksley WG: Pegylated interferons for chronic hepatitis B. Antiviral Res 2003, 60: 87-89. 10.1016/j.antiviral.2003.08.015View ArticlePubMedGoogle Scholar
  28. Chang T, Suh DJ: Current approaches for treating chronic hepatitis B: when to start, what to start with, and when to stop. Hepatol Int 2008, 2: S19-S27. 10.1007/s12072-008-9059-0View ArticleGoogle Scholar
  29. Lau JYN, Bain VG, Naomov NV, Smith HM, Alexander GJ, Williams R: Effect of interferon-a on hepatits B viral antigen expression in primary hepatocyte culture. Hepatology 1991, 14: 9759.Google Scholar
  30. Guan R: Interferon monotherapy in chronic hepatitis B. J Gastroenterol Hepatol 2000, 15: 34-40. 10.1046/j.1440-1746.2000.02101.xView ArticleGoogle Scholar
  31. Naeem MA, Khan I, Waris J, Usman M: Efficacy of Interferon therapy in patients of chronic hepatitis B viral infection treated at MH Rawalpindi. Professional Med J 2008, 15: 380-386.Google Scholar
  32. Zuberi BF, Quraishy MS, Afsar S, Akhtar N, Kumar A, Dodani SK: Treatment outcome in patients of hepatitis B with hepatitis D: Experience of 4 years at a tertiary care centre in Pakistan. J Coll Physicians Surg Pak 2007, 17: 320-322.PubMedGoogle Scholar
  33. Okushin H, Ohnishi T, Morii K, Uesaka K, Yuasa S: Short-term intravenous interferon therapy for chronic hepatitis B. World J Gastroenterol 2008, 14: 3038-3043. 10.3748/wjg.14.3038PubMed CentralView ArticlePubMedGoogle Scholar
  34. Cooksley WG, Piratvisuth T, Lee SD, Mahachai V, Chao YC, Tanwandee T, Chutaputti A, Chang WY, Zahm FE, Pluck N: Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003, 10: 298-305. 10.1046/j.1365-2893.2003.00450.xView ArticlePubMedGoogle Scholar
  35. Okamoto H, Tsuda F, Sakugawa H, Sastrosoewinjo RI, Imai M, Miyakawa Y, Mayumi M: Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J Gen Virol 1988, 69: 2575-2583. 10.1099/0022-1317-69-10-2575View ArticlePubMedGoogle Scholar
  36. Huy T, Ngoc T, Abe K: New complex recombinant genotype of hepatitis B virus identified in Vietnam. J Virol 2008, 82: 5657-5663. 10.1128/JVI.02556-07PubMed CentralView ArticleGoogle Scholar
  37. Yu H, Yuan Q, Ge SX, Wang HY, Zhang YL, Chen QR, Zhang J, Chen PJ, Xia NS: Molecular and phylogenetic analyses suggest an additional.Hepatitis B virus genotype ''I''. PLoS One 2010, 5: 9297. 10.1371/journal.pone.0009297View ArticleGoogle Scholar
  38. Awan Z, Idrees M, Amin I, et al.: Pattern and Molecular Epidemiology of Hepatitis B virus genotypes circulating in Pakistan. Infect Genet Evol 2010, 10: 1242-1246. 10.1016/j.meegid.2010.08.006View ArticlePubMedGoogle Scholar
  39. Ahmed CS, Wang ZH, Bin Z, Chen JJ, Kamal M, Hou JL: Hepatitis B virus genotypes, subgenotypes, precore, and basal core promoter mutations in the two largest provinces of Pakistan. J Gastroenterol Hepatol 2009, 24: 569-73. 10.1111/j.1440-1746.2008.05642.xView ArticlePubMedGoogle Scholar
  40. Baig S, Siddiqui A, Chakravarty R, Moatter T: Hepatitis B virus subgenotypes D1 and D3 are prevalent in Pakistan. BMC Research Notes 2009, 2: 1. 10.1186/1756-0500-2-1PubMed CentralView ArticlePubMedGoogle Scholar
  41. Noorali S, Hakim ST, McLean D, Kazmi SU, Bagasra O: Prevalence of Hepatitis B virus genotype D in females in Karachi, Pakistan. J Infect Developing Countries 2008, 2: 373-378.Google Scholar
  42. Hakim ST, Kazmi SU, Bagasra O: Seroprevalence of hepatitis B and C genotypes among yung apparently healthy females of Karachi-Pakistan. Libyan J Med 2008, 3: 66-70. AOP: 071123 10.4176/071123PubMed CentralView ArticlePubMedGoogle Scholar
  43. Alam MM, Zaidi SZ, Shaukat S, Sharif S, Angez M, Naeem A, et al.: Common Genotypes of Hepatitis B virus prevalent in Injecting drug abusers (addicts) of North West Frontier Province of Pakistan. Virology J 2007, 4: 63. 10.1186/1743-422X-4-63View ArticleGoogle Scholar
  44. Baig S, Siddiqui AA, Ahmed W, Qureshi H, Arif A: The association of complex liver disorders with HBV genotypes prevalent in Pakistan. Virology J 2007, 4: 128. 10.1186/1743-422X-4-128View ArticleGoogle Scholar
  45. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS: Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000, 33: 998-1002. 10.1016/S0168-8278(00)80135-XView ArticlePubMedGoogle Scholar
  46. Wai CT, Chu CJ, Hussain M, Lok AS: HBV genotype B is associated with better response to interferon therapy in HBeAg-positive chronic hepatitis than genotype C. Hepatology 2002, 36: 1425-30.PubMedGoogle Scholar
  47. Janssen HLA, Senturk H, Zeuzem S, Akarka U, Cakalluglu Y, Simon K, et al.: Peginterferon alfa 2b and lamivudine combination therapy compared withpeginterferon alfa 2b for chronic HBeAg positive hepatitis B: randomized controlled trial in 307 patients. Hepatology 2003, 38: 1323.Google Scholar
  48. Erhardt A, Gobel T, Ludwig A: Response to antiviral treatment in patients infected with hepatitis B virus genotypes E-H. J Med Virol 2009, 81: 1716-1720. 10.1002/jmv.21588View ArticlePubMedGoogle Scholar

Copyright

© Ali et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.